Loading...
Having trouble viewing this email? View it as a Web page. You are receiving this message because you are subscribed to News Releases for National Institutes of Health (NIH). Long-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV 03/06/2024 10:30 AM ESTNIH-funded research networks provide evidence on cabotegravir and rilpivirine in additional populations.
|
Loading...
Loading...